temozolomide has been researched along with Soft Tissue Neoplasms in 7 studies
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma." | 9.11 | A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005) |
| "The authors conducted a two-arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in patients with gastrointestinal stromal tumors (GISTs; Arm 2)." | 9.10 | A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. ( Beach, J; Benjamin, RS; Burgess, MA; Chen, LL; Papadopolous, N; Patel, SR; Trent, JC, 2003) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 9.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the anticancer effects of cabozantinib, temozolomide, and their combination in uterine sarcoma cell lines and mouse xenograft models." | 8.12 | Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. ( Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Lee, JW; Noh, JJ; Ryu, JY, 2022) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 5.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| "The objective of this study was to evaluate the activity and toxicity of temozolomide given as an extended schedule in patients with advanced sarcoma." | 5.11 | A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005) |
| "The authors conducted a two-arm Phase II study of temozolomide to determine its efficacy and toxicity in patients with soft tissue sarcomas (STSs) who had received, had refused, or were not eligible for standard chemotherapy with doxorubicin and ifosfamide (Arm 1) and in patients with gastrointestinal stromal tumors (GISTs; Arm 2)." | 5.10 | A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. ( Beach, J; Benjamin, RS; Burgess, MA; Chen, LL; Papadopolous, N; Patel, SR; Trent, JC, 2003) |
| "Temozolomide has shown efficacy in the treatment of metastatic melanoma similar to that of dacarbazine (DTIC), the standard chemotherapy, but with the added benefit of penetration into the central nervous system (CNS)." | 5.10 | Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. ( Brampton, MH; Calvert, AH; Middleton, MR; Paul, MJ; Rustin, G; Summers, Y; Thatcher, N, 2002) |
| "To evaluate the anticancer effects of cabozantinib, temozolomide, and their combination in uterine sarcoma cell lines and mouse xenograft models." | 4.12 | Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma. ( Cho, YJ; Choi, JJ; Choi, JY; Hwang, JR; Lee, JW; Noh, JJ; Ryu, JY, 2022) |
| "A 33-year-old woman presented with rare brain metastases from undifferentiated high-grade sarcoma manifesting as headache and vomiting." | 1.36 | Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report. ( Arai, A; Itoh, T; Kanomata, N; Kawamura, A; Kohmura, E; Nishihara, M; Sasayama, T; Tanaka, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Noh, JJ | 1 |
| Cho, YJ | 1 |
| Ryu, JY | 1 |
| Choi, JJ | 1 |
| Hwang, JR | 1 |
| Choi, JY | 1 |
| Lee, JW | 1 |
| Moukhlissi, M | 1 |
| Naciri, F | 1 |
| Paulino, AC | 1 |
| Pappo, A | 1 |
| Tanaka, H | 1 |
| Sasayama, T | 1 |
| Nishihara, M | 1 |
| Arai, A | 1 |
| Kawamura, A | 1 |
| Kanomata, N | 1 |
| Itoh, T | 1 |
| Kohmura, E | 1 |
| Trent, JC | 1 |
| Beach, J | 1 |
| Burgess, MA | 1 |
| Papadopolous, N | 1 |
| Chen, LL | 1 |
| Benjamin, RS | 1 |
| Patel, SR | 1 |
| Garcia del Muro, X | 1 |
| Lopez-Pousa, A | 1 |
| Martin, J | 1 |
| Buesa, JM | 1 |
| Martinez-Trufero, J | 1 |
| Casado, A | 1 |
| Poveda, A | 1 |
| Cruz, J | 1 |
| Bover, I | 1 |
| Maurel, J | 1 |
| Paul, MJ | 1 |
| Summers, Y | 1 |
| Calvert, AH | 1 |
| Rustin, G | 1 |
| Brampton, MH | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for temozolomide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Gastroint | 2003 |
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administrati | 2005 |
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Brain Neoplasms; Case-Control Stu | 2002 |
4 other studies available for temozolomide and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Anticancer Activity of the Combination of Cabozantinib and Temozolomide in Uterine Sarcoma.
Topics: Anilides; Animals; Apoptosis; Cell Line, Tumor; Female; Humans; Leiomyosarcoma; Mice; Pyridines; Sar | 2022 |
[Exceptional metastasis of glioblastoma].
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Gl | 2015 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Mod | 2009 |
Brain metastasis of undifferentiated sarcoma and response to temozolomide treatment. Case report.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; D | 2010 |